PTGS2 and rheumatoid arthritis: To investigate whether COX-2 inhibitors have a disease-modifying effect by rescuing subchondral bone structure in genetically modified mice with RA, we gavage-fed the COX-2 inhibitor celecoxib to TNF-α transgenic mice at a dose of 8 mg·kg–1 daily for 4 weeks.